Molnupiravir 200mg capsules
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Molnupiravir
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Molnupiravir
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Molnupiravir on the MHRA register
Lagevrio 200mg capsules
WHO defined daily dose (DDD)
1.6 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(5)
Molnupiravir for treating COVID-19 (TA1056)
COVID-19 rapid guideline: managing COVID-19 (NG191)
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 (TA878)
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 8 · Randomised trials: 10 · 2021–2026
Showing the 50 most relevant studies, sorted by most relevant.
Moghadam SHP, Sarkoohi A, Navidi Z, et al.
2025
- Hydroxylamines
- Alanine
- Cytidine
Julia Richmond DiBello, Valerie T. Raziano, Xinyue Liu, et al.
Infectious Diseases and Therapy, 2024
Shen-Hua Lin, Jen-Wei Liu, Yi-Ti Yen, et al.
Journal of Microbiology, Immunology and Infection, 2025
Okoli GN, Askin N, Rabbani R
2026
- Hydroxylamines
- Cytidine
- Antiviral Agents
Tatz GS, Ochodo EA, Fox T, et al.
2025
- Hydroxylamines
- Cytidine
- Antiviral Agents
Huzaifa Ahmad Cheema, Saleha Abdul Rab, Momina Butt, et al.
Journal of Microbiology, Immunology and Infection, 2024
Louis D Saravolatz, Shawn Depcinski, Mamta Sharma
Clinical Infectious Diseases, 2022
Joseph F. Standing, Laura Buggiotti, Jose Afonso Guerra-Assuncao, et al.
Nature Communications, 2024
Yayun Liu, Shiyong Fan, Aijing Xu, et al.
Frontiers in Pharmacology, 2023
Mickie H. Cheng, Alex J. Mann, Brian M. Maas, et al.
Pulmonary Therapy, 2025
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
None known
Half-life
3.3 hours
Mechanism
Molnupiravir is hydrolyzed in vivo to N4-hydroxycytidine, which is phosphorylate…
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
800 mg
Half-life
3.3 hours
[L39055]
Protein binding
[L39055]
Metabolism
[A193026]
…
Elimination
3%
[L39055]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to COVID-19 in adults.[L39050] Molnupiravir was also granted emergency use authorization by the FDA on December 23, 2021; however, it is not yet fully approved.[L39588]
[A193014][A193029]
Molnupiravir is approved in the UK for reducing the risk of hospitalization and death in mild to moderate COVID-19 cases for patients at increased risk of severe disease (eg. with obesity, diabetes mellitus, heart disease, or are over 60 years old).
[L39050][L39055]
In the US, molnupiravir is authorized for emergency use for the treatment of high-risk adults With mild to moderate COVID-19.
[L39588]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L39055]
[L39055]
[L39055]
[A193026]
Once inside cells, N4-hydroxycytidine is phosphorylated to the 5'-triphosphate form.
[A193026]
[L39055]
ATC J05AB18
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Molnupiravir
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72